© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
June 04, 2018
Combining pegilodecakin (AM0010) with nivolumab (Opdivo) or pembrolizumab (Keytruda) induced an overall response rate (ORR) of 41% in patients with advanced non–small cell lung cancer (NSCLC), according to findings from an early phase study presented at the 2018 ASCO Annual meeting.